Anti-Cancer Agents and Biological Therapy
Clinical Pharmacology of Anti-Cancer Agents
Oncological Emergencies
Latest ESMO videos
Featured medwireNews
Multidisciplinary Assessment Reduces Chemotherapy Toxicity For Older Cancer Patients
BrighTNess: Long-Term Event-Free Survival Supports TNBC Neoadjuvant Carboplatin Use
Five-year AI Extension Increases Fracture Risk Without Reducing Breast Cancer Recurrence
New-Generation TKIs Linked To CML Hepatotoxicity
Long-Term COLUMBUS Data Confirm Encorafenib–Binimetinib PFS Benefit in Advanced Melanoma
E-Learning
ESMO E-Learning: PARP Inhibitors: Past, Present and Future
ESMO E-Learning: Cardiotoxicity in Oncology Practice
ESMO E-Learning: Multimodular Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
ESMO V-Learning: BRCA Across Tumour Types
ESMO E-Learning: Next Generation Drugs in Kidney Cancer
Meeting resources
Targeting mRNA translation initiation in melanoma
Presenter: Stephan Vagner
Session: Transcription and translation inhibitors in cancer treatment
Resources:
Slides
Webcast
HDAC inhibitor romidepsin in cancer
Presenter: Susan Bates
Session: Transcription and translation inhibitors in cancer treatment
Resources:
Slides
Webcast
Exploring and therapeutically exploiting the tumour microenvironment
Presenter: Johanna Joyce
Session: Gordon Peters lecture
Resources:
Webcast
Invited discussant: 1MO, 2MO and3MO
Presenter: Julian Downward
Session: Mini Oral session
Resources:
Slides
Webcast
2MO - XPO1 inhibition strongly sensitizes to first and second line therapy in small cell lung cancer
Presenter: alvaro Quintanal-Villalonga
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast